Kenneth Frazier

Last updated
Kenneth Frazier
Kenneth C. Frazier.jpg
Born
Kenneth Carleton Frazier

(1954-12-17) December 17, 1954 (age 69)
Education Pennsylvania State University, University Park (BA)
Harvard University (JD)
Occupation(s)Executive chairman, Merck & Co.

Kenneth Carleton Frazier (born December 17, 1954) is an American business executive. He is executive chairman and former CEO of the pharmaceutical company Merck & Co. (known as MSD outside of North America). After joining Merck & Co. as general counsel, he directed the company's defense against litigation over the anti-inflammatory drug Vioxx. Frazier is the first African American man to lead a major pharmaceutical company (part of the Fortune 500 companies). [1] He was elected to the American Philosophical Society in 2018. [2]

Contents

Frazier was included in Time's list of the most influential people in the world in 2018 and 2021. [3] [4]

Early life and education

Kenneth Frazier was born on December 17, 1954, in North Philadelphia. [5] His father, Otis, was a janitor. [5] [6] Frazier has said Thurgood Marshall was one of his heroes growing up. [7] Frazier's mother died when he was twelve years old. [5] He attended Julia R. Masterman School and Northeast High School. [8] After graduating at age 16, he entered Pennsylvania State University. [7] To make extra money in college, he raised tadpoles and newts and sold them to local stores. [9]

After earning his B.A. from Penn State, Frazier enrolled at Harvard Law School and graduated in 1978 with a J.D. [6] [10]

Career

Drinker Biddle

After graduating from Harvard, Frazier began his law career with Drinker Biddle & Reath in Philadelphia. [7] In 1991, Esther F. Lardent, head of the Death Penalty Representation Project, asked Frazier to defend death-row inmate James Willie "Bo" Cochran. [5] Cochran had been arrested and accused of murdering an assistant manager at a Birmingham grocery store in 1976. [11] Frazier, then a partner at Drinker Biddle, and two colleagues took the case. [9] In 1995, after 19 years on death row, the United States Courts of Appeals for the Eleventh Circuit overturned Cochran's conviction. In 1997, Cochran was retried and found not guilty. [11] Frazier continued to represent him after leaving Drinker Biddle. During Frazier's law career, he also took four summer sabbaticals to teach trial advocacy in South Africa. [6]

Merck & Co.

Frazier meets with President Donald Trump in January 2017 President Donald Trump listens to Kenneth Frazier, chairman and CEO of Merck & Co.jpg
Frazier meets with President Donald Trump in January 2017
Frazier at an event with President Joe Biden and Alex Gorsky in March 2021

As a lawyer at Drinker Biddle, one of Frazier's clients was Merck & Co., the second-largest drug company in the United States. [7] [9] In 1992, he joined Merck's public affairs division as general counsel. [7] [12] Frazier was named senior general counsel in 1999. [13] As general counsel, he was credited with overseeing the company's defense against claims that the anti-inflammatory drug Vioxx had caused heart attacks and strokes. [9] [13] [14] Analysts at the time estimated Merck's liability to range from 20 to 50 billion dollars. [15] Frazier said the case was "the most significant challenge [he'd] ever faced." [9] He chose to fight all cases in court rather than settle them all quickly. [12] The remaining cases were settled in 2007 for $4.85 billion. [13]

In 2006, Frazier was promoted to executive vice president in addition to his role as general counsel. [13] He led the company's largest group, Human Health, from 2007 until he was named president of Merck in April 2010. [7] [16] On January 1, 2011, he became CEO and a member of the company's board of directors, replacing former Merck CEO Richard Clark. [7] [17] Frazier is the first African-American to lead a major pharmaceutical company. [5]

As CEO, Frazier has directed the company to take financial risks in developing new treatments. [15] In 2013, he prioritized research funding over meeting the year's earnings target. [12] He has placed special emphasis on improving treatments for Alzheimer's disease. Frazier's father died from Alzheimer's. Frazier has said he is also motivated at Merck by a desire to improve the lives of people in developing countries. [15]

Frazier received a total compensation of $21,387,205 in 2014; $17,023,820 in 2015; and $21,781,200 in 2016. [18] [19] On February 26, 2017, it was reported Frazier owned 600,304 shares of Merck stock worth approximately $37,000,000. [20] Based on stock transactions at Merck alone and his tenure at the company, his net worth is in the hundreds of millions. [21] As of December 31, 2016, Mr. Frazier was eligible for early retirement subsidies under the Qualified Plan and SRP with a pension valued at $26,593,261. [22] In the "annual collaborative report" from Equilar and The New York Times, Frazier [23] ranked 66th in the May 2015 list of "200 highest-paid CEOs of large publicly traded companies" and seventh in the list of biopharmaceutical executives with the highest total compensation. [24]

In July 2016, Frazier sold 60,000 shares of the firm's stock. The stock was sold at an average price of $64.44. [25] In the years 2018, 2019 and 2020 respectively Frazier sold 787,792, 694,698 and 280,000 shares of the firm's stock with a total value at time of sale of $110.23 million. On February 4, 2021, Merck announced that Frazier would be retiring as president and CEO at the end of June, while remaining executive chairman. [26]

Licensing litigation

Merck deceptively obtained the formula to Sovaldi over a conference call with Pharmasset. [27] [28] In March 2004, Pharmasset was willing to reveal details of its formulas on the call because it was led to believe everyone on the call would be subject to the confidentiality agreement. But the participants included Merck patent attorney Phillippe Durette, who wasn't firewalled and was in a position to turn what he heard into a potential goldmine for Merck. Durette lied about being on the conference call under oath and then Merck's legal team advised him to blame it on poor memory. In a deposition, he repeatedly denied having been on the call. He recanted at trial only after he was confronted with notes taken by a Pharmasset employee during the call, proving that he had participated. At that point, he pleaded a faulty memory. Judge Freeman didn't buy it. "It is overwhelmingly clear...," she ruled, "that Dr. Durette sought at every turn to create the false impression that Merck's conduct was aboveboard." She blamed Merck, which she said "sponsored and encouraged" his conduct, then sought to minimize its importance by attributing the fiasco to "the failed memory of a retired employee." Federal Judge Beth Labson Freeman described the company's behavior as "systematic and outrageous deception in conjunction with unethical business practices and litigation misconduct." That conduct included "lying to Pharmasset, misusing Pharmasset's confidential information, breaching confidentiality and firewall agreements, and lying under oath at deposition and trial." [29] [27] [28]

In 2017, Merck said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda. Bristol and Ono, which co-developed the first PD-1 antibody called Opdivo, filed the suit against Merck in September 2014, alleging that its sale of Keytruda, also a PD-1 antibody, infringed their patents in markets including the United States, parts of Europe, Australia and Japan. Merck will make an initial payment of $625 million to Bristol and Japan's Ono. The company will also pay a 6.5-percent royalty rate on Keytruda sales from January 2017 to December 2023, and a 2.5-percent rate for the subsequent three years. [30] In the first two months of 2017, sales of Keytruda in the US jumped to roughly $260 million, an 80-percent increase compared with the same period the previous year, according to IMS, a data provider that tracks medicine sales. [31]

Other work

Frazier currently serves on the board of directors of Merck (as executive chairman), the National Constitution Center, and Eikon Therapeutics. [32] [33] Previously, Frazier served on the board of ExxonMobil from 2009 to 2022 and of the Pharmaceutical Research and Manufacturers of America from 2011 to 2021. Frazier presently is a trustee of Cornerstone Christian Academy in Philadelphia. [34]

In November 2011, the Pennsylvania State University board of trustees appointed Frazier (a trustee) to serve as chairman of a special committee investigation into the child sex abuse scandal involving former assistant football coach Jerry Sandusky and allegations of a cover up by university officials. [35] [36] Frazier was criticized by Harrisburg attorney William Cluck for his handling of the Sandusky scandal, particularly its decision to rely on the Louis Freeh Report, which found emails suggesting that university leaders, including head football coach Joe Paterno, knew of reports of Sandusky's sex abuse but failed to report it. At a meeting, when Cluck questioned the Freeh report, Frazier directed a fiery criticism at Cluck and Paterno defenders, [37] [38] saying, "I believe that we are entitled to look at the words and contemporaneous emails and other documents that draw the conclusions that we need to draw as a university. We are not subject to the criminal beyond-a-reasonable-doubt standard [...] If you cared about that, you are one of the few people in this country that looks like you who actually believes the O.J. Simpson not guilty verdict was correct. The fact of the matter is, those documents say what they say, and no amount of hand-waving will ever change what those documents say." [38] Frazier twice apologized for the outburst. [39]

Frazier is a member of the American Law Institute and serves on its council. In May 2013, he delivered the keynote speech at the ALI Annual Dinner. [40]

Frazier was a member of President Trump's American Manufacturing Council. He resigned from the Council on August 14, 2017, [41] following the violent 2017 Unite the Right rally in Virginia. In a statement, Frazier said that he objected to Trump's statement that "many sides" were responsible for violence. Frazier stated, "America's leaders must honor our fundamental views by clearly rejecting expressions of hatred, bigotry and group supremacy, which run counter to the American ideal that all people are created equal." [42] [43]

On June 1, 2020, Frazier gave an interview with CNBC Squawk Box addressing racial tensions and violence following the murder of George Floyd, an unarmed black man who was murdered by the Minneapolis police. In the interview, he mentioned that it could have been him in that situation. [44]

In August 2020, Kenneth Frazier and his wife, Andréa Frazier donated $5 million to Jefferson Health to work with Temple University on a new stroke initiative targeting African-American communities. [45] [46]

See also

Related Research Articles

<span class="mw-page-title-main">Joe Paterno</span> American football player and coach (1926–2012)

Joseph Vincent Paterno, sometimes referred to as JoePa, was an American college football player, athletic director, and coach. He was the head coach of the Penn State Nittany Lions from 1966 to 2011. With 409 victories, Paterno is the most victorious coach in NCAA FBS history. He recorded his 409th victory on October 29, 2011; his career ended with his dismissal from the team on November 9, 2011, as a result of the Penn State child sex abuse scandal. He died 74 days later, of complications from lung cancer.

<span class="mw-page-title-main">Graham Spanier</span> American sociologist and university administrator

Graham Basil Spanier is a South African-born American sociologist and university administrator who became the 16th president of Pennsylvania State University on September 1, 1995. On November 9, 2011, in the wake of the Penn State child sex abuse scandal, Spanier and longtime football coach Joe Paterno were “removed from their positions” by the Penn State board of trustees.

William Allen Schreyer was chairman emeritus and former CEO of Merrill Lynch & Co., where he worked for 45 years total, eight of them as chairman and CEO. He was also a noted philanthropist and served as former president of Pennsylvania State University's Board of Trustees.

<span class="mw-page-title-main">Judy Lewent</span>

Judith Carol Lewent is a business executive who served as chief financial officer of Merck & Co. from 1990 until her retirement from the company in 2007. Since her retirement from Merck, she has continued to serve on multiple corporate boards, including the boards of GlaxoSmithKline, Thermo Fisher Scientific and Motorola Solutions. She also served on the board of Purdue Pharma until her departure from the company in 2014.

<span class="mw-page-title-main">Richard Clark (business executive)</span>

Richard T. Clark is a former chairman of the Merck & Co. (MSD) pharmaceutical company, a position he held from 2007 to 2011. His previous leadership positions at Merck & Co. include CEO (2005–2010), president (2005–2009) and president of the Merck & Co. manufacturing division (2003–2005).

Mylan N.V. was a global generic and specialty pharmaceuticals company. In November 2020, Mylan merged with Upjohn, Pfizer's off-patent medicine division, to form Viatris. Previously, the company was domiciled in the Netherlands, with principal executive offices in Hatfield, Hertfordshire, UK and a "Global Center" in Canonsburg, Pennsylvania, US.

<span class="mw-page-title-main">P. Roy Vagelos</span> American physician and business executive

Pindaros Roy Vagelos is an American physician and business executive, who was president and chief executive officer (1985) and chairman (1986) of the American pharmaceutical company Merck & Co..

Raymond V. Gilmartin is an American former business executive and an adjunct professor of management practice at the Harvard Business School.

<span class="mw-page-title-main">Winston & Strawn</span> American law firm

Winston & Strawn LLP is an international law firm headquartered in Chicago. It has more than 900 attorneys spread across ten offices in the United States and six offices in Europe, Asia and South America. Founded in 1853, it is one of the largest and oldest law firms in Chicago.

Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.

John Lloyd Huck was a business executive, philanthropist, and aviation enthusiast. He was chairman of pharmaceutical firms Merck & Co. and Nova Pharmaceutical Corporation, as well as Mutual Benefit Life Insurance Company.

<span class="mw-page-title-main">Louis Freeh</span> Fifth Director of the FBI (born 1950)

Louis Joseph Freeh is an American attorney and former judge who served as the fifth Director of the Federal Bureau of Investigation from September 1993 to June 2001.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

The Penn State child sex abuse scandal concerned allegations and subsequent convictions of child sexual abuse committed by Jerry Sandusky, an assistant coach for the Penn State Nittany Lions football team, over a period of at least fifteen years. The scandal began to emerge publicly in March 2011 and broke in early November 2011 when Sandusky was indicted on 52 counts of child molestation, stemming from incidents that occurred between 1994 and 2009. Sandusky was ultimately convicted on 45 counts of child sexual abuse on June 22, 2012, and was sentenced to a minimum of 30 years and a maximum of 60 years in prison. Of the 10 victims who were listed, only eight appeared at trial. All were over the age of 18 by the time they testified. Six were over 21.

<span class="mw-page-title-main">Faegre Drinker</span> American law firm

Faegre Drinker Biddle & Reath, also known as Faegre Drinker, is a full-service international law firm and one of the 100 largest law firms in the United States. Formed in February 2020 by the merger of Faegre Baker Daniels LLP and Drinker Biddle & Reath, the firm provides legal counseling and litigation to a wide range of clients across many practice areas.

<span class="mw-page-title-main">Incyte</span> American pharmaceutical company

Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware, and Morges, Switzerland. The company was created in 2002 through the merger of Incyte Pharmaceuticals, founded in Palo Alto, California in 1991 and Incyte Genomics, Inc. of Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia.

<span class="mw-page-title-main">Karl-Ludwig Kley</span> German manager

Karl-Ludwig Kley is a German business executive.

<span class="mw-page-title-main">Stefan Oschmann</span> German businessman (born 1957)

Stefan Oschmann is a German businessman. He was the CEO of pharma group Merck.

<span class="mw-page-title-main">Michael Bonney</span> American businessman and former pharmaceutical executive

Michael "Mike" Weston Bonney is an American businessman and former pharmaceutical executive. Bonney was the president and chief executive officer of Cubist Pharmaceuticals, from 2003 until his retirement in 2014 coinciding with the company being acquired by Merck & Co. for $9.5 billion.

Raymond F. Schinazi is an Egyptian organic medicinal chemist at Emory University with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, including molecular modeling and gene therapy.

References

  1. Davis, Dominic-Madori. "There are only four black Fortune 500 CEOs. Here they are". Business Insider. Retrieved 2020-03-04.
  2. "Election of New Members at the 2018 Spring Meeting".
  3. Trinacria, Joe (April 19, 2018). "A Pair of Philadelphians Made Time's 100 Most Influential People List". Philadelphia . Retrieved November 13, 2021.
  4. "Kenneth Frazier And Sherrilyn Ifill Among Time's Most Influential People of 2021". American Law Institute . September 21, 2021. Retrieved November 13, 2021.
  5. 1 2 3 4 5 Rice, Lewis I. (Summer 2011). "A Dose of Optimism". Harvard Law Bulletin.
  6. 1 2 3 Chen, Vivia (February 13, 2002). "Master of the Game" . The Minority Law Journal.
  7. 1 2 3 4 5 6 7 Hepp, Christopher K. (December 1, 2010). "New Merck CEO Kenneth C. Frazier has Philadelphia roots". Philadelphia Inquirer.
  8. "Kenneth Frazier born". African American Registry. Retrieved 2020-03-04.
  9. 1 2 3 4 5 "Merck New CEO Frazier Vows Innovation, Wider Markets". Bloomberg. November 30, 2010.
  10. "President Obama Announces More Key Administration Posts". whitehouse.gov . The White House. September 18, 2013 via National Archives.
  11. 1 2 Rogers, Lisa (March 26, 2005). "Cochran continues to inspire". Gadsden Times. p. B1.
  12. 1 2 3 Randall, Tom (March 21, 2011). "Merck's Risky Bet on Research". Bloomberg Businessweek. Archived from the original on April 30, 2011.
  13. 1 2 3 4 Pierson, Ransdell; Krauskopf, Lewis (November 30, 2010). "Merck elevates Frazier to succeed Clark as CEO". Reuters.
  14. Koppel, Nathan (November 30, 2010). "Another Lawyer Done Good: Merck Names Frazier CEO". Wall Street Journal / Law Blog.
  15. 1 2 3 Johnson, Linda A. (March 1, 2012). "CEO: Risks Key for Merck to Succeed, Help Patients". Associated Press. Archived from the original on February 21, 2014.
  16. "Biographical Info on Merck CEO-Elect Frazier". Yahoo News. Associated Press. November 30, 2010.
  17. "Merck's CEO to get $1.5 million yearly, incentives". BusinessWeek. Associated Press. December 1, 2010. Archived from the original on October 25, 2012.
  18. Salary.com, Site built by. "Compensation Information for Kenneth C. Frazier, Chairman, President and Chief Executive Officer of MERCK & CO | Salary.com". Salary.com. Retrieved 2017-08-15.
  19. "Stock Quotes & Company News". Reuters. Retrieved 2017-08-15.[ dead link ]
  20. "MRK Major Holders | Merck & Company, Inc. (new) Stock – Yahoo Finance". finance.yahoo.com. Retrieved 2017-08-15.
  21. "Stock Screener – Yahoo Finance". finance.yahoo.com. Retrieved 2017-08-15.
  22. http://s21.q4cdn.com/488056881/files/doc_financials/2016/annual/MRK004_PXY_Bookmarked.pdf [ bare URL PDF ]
  23. "Biopharma execs have big presence among top-paid CEOs".
  24. Gray, Nicole (29 May 2015), "Biopharma execs have big presence among top-paid CEOs", BioPharma Dive, retrieved 19 November 2015
  25. Graham, Teresa. "Merck & Co. (MRK) CEO Kenneth C. Frazier Sells 60,000 Shares". The Cerbat Gem. Retrieved 6 July 2016.
  26. "Merck's Ken Frazier, one of just 4 Black CEOs in the Fortune 500, is stepping down".
  27. 1 2 Hiltzik, Michael (2016-06-09). "Big Pharma bombshell: Judge finds Merck lied in patent trial, overturns $200-million verdict". Los Angeles Times. ISSN   0458-3035 . Retrieved 2017-08-15.
  28. 1 2 "Merck, Bristol-Myers agree to settle Keytruda patent suit". Reuters. 2017-01-20. Retrieved 2017-08-15.
  29. "A Merck Lawyer's 'Failed Memory Rings Hollow,' Judge Rules" . Retrieved 2017-08-15.
  30. "Merck, Bristol-Myers agree to settle Keytruda patent suit". Reuters. January 20, 2017. Retrieved 2017-08-15.
  31. Crow, David (2017-04-03). "Merck's Keytruda cancer drug records sales surge" . Financial Times. Retrieved 2017-08-15.
  32. "Kenneth C. Frazier". Merck.com. Retrieved 2022-06-17.
  33. "Eikon Therapeutics Announces the Election of Kenneth C. Frazier to Its Board of Directors". www.businesswire.com. 2022-03-31. Retrieved 2022-06-17.
  34. "In Honor of Visionary Leader, PhRMA Announces the Kenneth C. Frazier PhRMA Scholars Program". phrma.org. Retrieved 2022-06-17.
  35. Sisak, Michael R. (November 11, 2011). "Committee promises thorough investigation of sex abuse at PSU". The Citizens' Voice.
  36. NJ Advance Media for NJ.com, Matthew Stanmyre, Penn State appoints Kenneth Frazier to lead special committee investigating child sex-abuse scandal, (November 11, 2011).
  37. Thompson, Charles (March 14, 2013). "Penn State trustee Ken Frazier fires back at Freeh Report critics". The Patriot-News / PennLive.
  38. 1 2 Mike Dawson, Penn State trustee Frazier bashes critics, dismisses Paterno report in spat with candidate, Centre Daily Times (March 15, 2013).
  39. Kador, John (March 22, 2013). "Apology of the Week: Penn State Trustee and Merck & Co. CEO Kenneth Frazier Apologizes". BK Connection. Retrieved November 22, 2015.
  40. AmericanLawInstitute (24 May 2013). "Remarks by Kenneth C. Frazier at ALI Annual Dinner" via YouTube.
  41. "CEOs of Under Armour, Intel & Merch [sic] quit Trump's manufacturing council". fox4now.com. CNN. August 14, 2017. Retrieved 15 August 2017.
  42. Thrush, Glenn (August 14, 2017). "Trump Attacks Merck Chief Kenneth Frazier for Quitting Advisory Panel". New York Times.
  43. Andrew Ross Sorkin / nytimes.com 14 August 2017: Merck’s C.E.O. Took a Stand. What About Other Executives? (Opinion piece)
  44. Lucas, Amelia (2020-06-01). "Merck CEO Kenneth Frazier: George Floyd 'could be me'". CNBC. Retrieved 2020-06-03.
  45. "Jefferson Receives $5 Million Gift to Create Stroke Initiative with Temple". giving.jefferson.edu. Retrieved 2020-09-28.
  46. "$5M donation from Merck CEO, wife to support stroke care at Jefferson Health". www.beckershospitalreview.com. 2 September 2020. Retrieved 2020-09-28.